^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Colon Cancer

    Related cancers:
    19h
    SURGE: Survivors Uniting for Remote Guided Exercise (clinicaltrials.gov)
    P=N/A, N=300, Not yet recruiting, Colorado State University
    New trial
    20h
    EVICTION: First-in-Human Study of ICT01 in Patients With Advanced Cancer (clinicaltrials.gov)
    P1/2, N=292, Active, not recruiting, ImCheck Therapeutics | Trial completion date: Dec 2025 --> Oct 2026 | Trial primary completion date: Sep 2025 --> Oct 2026
    Trial completion date • Trial primary completion date • Checkpoint inhibition • First-in-human
    |
    Keytruda (pembrolizumab) • ICT01
    1d
    Abscopal-like antitumor effect induced by localized low-temperature plasma application of normal tissue in mice. (PubMed, J Radiat Res)
    No consistent changes were detected in CD8+ T-cell proportion or ICOS (inducible T-cell costimulatory) expression. However, the lack of antitumor effects in immunodeficient mice suggests that CD8+ T cells are involved.
    Preclinical • Journal • IO biomarker
    |
    CD8 (cluster of differentiation 8) • ICOS (Inducible T Cell Costimulator)
    1d
    Identification of HLA class II-restricted T cell receptors against shared PIK3CA mutations in patients with epithelial cancers. (PubMed, Cancer Immunol Immunother)
    Autologous PBL, gene engineered to express the PIK3CAE545K-specific TCR, suppressed the in vitro growth of two cancer cell lines, which endogenously expressed the PIK3CAE545K neoantigen. This study identified three PIK3CA-specific TCRs against two shared mutations, restricted by common HLA-class II molecules, using antigen-experienced TIL and memory PBL from patients with epithelial cancers and may further allow the development of off-the-shelf T cell immunotherapy strategies targeting PIK3CA.
    Journal • IO biomarker
    |
    KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • CD4 (CD4 Molecule) • HLA-DPB1 (Major Histocompatibility Complex, Class II, DP Beta 1)
    |
    TP53 mutation • KRAS mutation • PIK3CA mutation
    1d
    Epithelial HO-1 regulates iron availability and promotes colonic tumorigenesis in a context-dependent manner. (PubMed, JCI Insight)
    Single-cell RNA sequencing of tumor epithelial cells revealed a shift from a proliferative to a stress-adaptive program with loss of HO-1. These findings identify epithelial HO-1 as a context-dependent regulator of tumorigenesis: protective against acute heme toxicity, but promoting iron-dependent oxidative damage and proliferation in the setting of chronic inflammation.
    Journal
    |
    HMOX1 (Heme Oxygenase 1)
    1d
    Incidence of AIDS-defining Illness by Cancer Status in an Observational Study among Medicaid Beneficiaries Living with HIV in the United States, 2001 - 2015. (PubMed, J Acquir Immune Defic Syndr)
    Incidence of new ADIs was elevated after cancer diagnosis. PWH undergoing cancer treatment may require careful observation for ADI development and potentially warrant consideration of immune-sparing cancer treatment regimens given prior data suggesting sustained decreases in CD4 cell counts after cancer treatment.
    Observational data • Reimbursement • US reimbursement • Journal
    |
    CD4 (CD4 Molecule)
    1d
    LUNA: Liver Surgery and Chemotherapy in Treating Patients With Colorectal Cancer With Liver Metastases That Can Be Removed by Surgery and Lung Metastases That Cannot Be Removed by Surgery (clinicaltrials.gov)
    P2, N=28, Terminated, M.D. Anderson Cancer Center | Active, not recruiting --> Terminated; < 75% participation
    Trial termination
    1d
    RCT of Mobile Apps & FitBit v. Usual Care (clinicaltrials.gov)
    P=N/A, N=107, Active, not recruiting, Weill Medical College of Cornell University | Trial completion date: Aug 2025 --> Jun 2026 | Trial primary completion date: Aug 2025 --> Jun 2026
    Trial completion date • Trial primary completion date
    2d
    Surgical Outcomes in Splenic Flexure Cancers: A Multicenter Comparison of Segmental vs. Extended Hemicolectomy (SPARROW Study) (clinicaltrials.gov)
    P=N/A, N=140, Enrolling by invitation, Acibadem University
    New trial
    3d
    PEPOH: Precision Physical Exercise for Personalized Onco-Hematology. (clinicaltrials.gov)
    P=N/A, N=150, Not yet recruiting, University of Salamanca
    New trial
    3d
    Study of Colorectal Cancer Screening Options (clinicaltrials.gov)
    P=N/A, N=2004, Completed, Kaiser Permanente | N=400 --> 2004
    Enrollment change
    |
    GUARDANT SHIELD
    3d
    GLOX-PEN: Study to Evaluate the Use of Surgical Gloves for the Prevention of Oxaliplatin-Induced Peripheral Neuropathy (clinicaltrials.gov)
    P=N/A, N=84, Recruiting, AC Camargo Cancer Center
    New trial
    |
    oxaliplatin